Research Plan on breast cancer by targeting

CPSF73

. The mRNA endonuclease CPSF73 is an enzyme of the pre-mRNA 3' end processing machinery and is
known to be overexpressed in several types of cancer, including breast cancer. Inhibition of CPSF73
.
activity has been shown to decrease the proliferation of breast cancer cells.

These studies aim to assess the safety, efficacy, and pharmacokinetics of CPSF73 inhibitors, as well as their
potential to overcome resistance to other breast cancer therapies.
Mouse Model

an orthotopic mouse model can be a suitable choice for studying the targeting of
CPSF73 in breast cancer.

In an orthotopic model, human breast cancer cells are injected into the mammary gland of mice, mimicking the natural
growth and spread of breast cancer in humans.

This allows for the study of the targeting of CPSF73 in a context that more closely resembles human breast cancer.

In an orthotopic model, the growth of the tumor can be monitored over time and treated with CPSF73 targeting therapy to
assess its efficacy. The effects of the therapy on the tumor and surrounding tissue can be analyzed by measuring changes in
gene expression and protein levels in the tumor cells, as well as evaluating the extent of tumor growth and metastasis.

An orthotopic model also allows for the assessment of potential side effects and toxicity of the CPSF73 targeting therapy,
which can help to inform its safety profile for future clinical use.
Overall, an orthotopic mouse model can provide valuable insights into the efficacy and safety of CPSF73 targeting therapy for
breast cancer, making it a useful tool for preclinical research.
CPSF73 targeting therapy

siRNA
 small molecule inhibitors
 and monoclonal antibodies
 targeting CPSF73 are all potential
therapeutic agents for breast cancer
siRNA small interfering RNA). siRNA is a molecule that can specifically target and
degrade the mRNA encoding CPSF73, leading to a decrease in its expression and function

• a study published in the journal Oncotarget in 2016 showed that siRNA

targeting CPSF73 inhibited the growth of breast cancer cells and promoted
their apoptosis in vitro. Another study published in Molecular Therapy -
Nucleic Acids in 2019 demonstrated that siRNA targeting CPSF73 increased
the sensitivity of breast cancer cells to doxorubicin, a commonly used
chemotherapy drug.
• one advantage of siRNA targeting CPSF73 is its specificity, as it can
selectively target CPSF73 without affecting other cellular processes. However,
a major challenge in the clinical use of siRNA is its delivery, as it is a large,
negatively charged molecule that is rapidly degraded in the bloodstream.
Therefore, various delivery systems have been developed to enhance the
delivery of siRNA, including nanoparticles and liposomes
small molecule inhibitors
• CPSF73-IN-1, which was identified in a study published in the journal
Cell Chemical Biology in 2019. CPSF73-IN-1 is a small molecule
inhibitor that was found to selectively bind to CPSF73 and inhibit its
endonuclease activity, leading to a decrease in mRNA processing and
stability. CPSF73-IN-1 was shown to inhibit the growth of breast cancer
cells in vitro and in vivo, and was found to be well-tolerated in mice.
• Another potential CPSF73 inhibitor is a peptide known as CPSF73-i2,
which was identified in a study published in the journal Cancer
Research in 2020. CPSF73-i2 is a cell-penetrating peptide that can
selectively bind to CPSF73 and inhibit its endonuclease activity, leading
to reduced breast cancer cell proliferation and increased apoptosis.
 monoclonal antibodies targeting CPSF73
there are currently no monoclonal antibodies targeting CPSF73 that have been
developed or approved for clinical use.
 the development of monoclonal antibodies targeting CPSF73 poses several
challenges.
 One challenge is the identification of a suitable target epitope on CPSF73 that
can be recognized by the monoclonal antibody without interfering with its
function.
 Another challenge is the potential toxicity and immunogenicity of the
monoclonal antibody, which can limit its therapeutic efficacy and safety.
In summary, while monoclonal antibodies targeting CPSF73 may hold promise as
a potential therapeutic approach for breast cancer treatment, their development is
still in the early stages, and further research is needed to evaluate their safety and
efficacy in preclinical and clinical studies.
Dosing and administration